Corticosteroids still represent one of the cornerstone treatment options for subjects hospitalized with coronavirus disease 2019 (COVID-19), especially for those suffering from a severe form of the disease [1–3]. Pulse methylprednisolone administered intravenously is a widely accepted treatment strategy for the induction of recession in subjects with acute flare or exacerbation of a background autoimmune disease, such as systemic lupus erythematosus, systemic vasculitis, or multiple sclerosis [4].
